查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1553623

脂质体阿霉素市场规模、份额、趋势分析报告：按产品、按应用、按分销管道、按地区、细分市场预测，2024-2030 年

Liposomal Doxorubicin Market Size, Share & Trends Analysis Report By Product, By Application (Multiple Myeloma, Ovarian Cancer, Breast Cancer), By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10个工作天内

价格
简介目录

脂质体阿霉素市场成长与趋势

Grand View Research, Inc.最新报告显示，预计2030年全球脂质体阿霉素市场规模将达18.9亿美元，2024年至2030年复合年增长率为6.3%。

等待美国FDA 和欧洲药品管理局核准的各种研发线产品的存在是该市场的关键特征之一。第一个脂质体阿霉素製剂于 1995 年推出。来自 Janssen Products 的 Doxil/Caelyx 以及来自 Teva Pharmaceutical Laboratories 的 LP & Myocet。 Doxil是脂质体阿霉素的品牌名称，目前正在开发中，预计一旦商业化，将在未来三到四年内产生巨大的价值。

美国FDA 药品生产核准的增加预计也将提振市场。这些药物用于治疗多种疾病的适应症不断扩大，包括与爱滋病相关的卡波西氏肉瘤、多发性骨髓瘤、神经母细胞瘤、骨癌和卵巢癌，这意味着需求的成长。克服不良健康影响的药物配方技术进步以及各种类型的药物传输系统（例如涂层奈米颗粒）的采用是推动药物需求的一些关键因素。

脂质体阿霉素主要核准用于治疗骨髓瘤、卡波西氏肉瘤和卵巢癌。然而，由于它也广泛用于其他疾病，2015年乳癌的收益占比最高，达21.2%。乳癌盛行率的增加导致对化疗的需求增加，化疗占了收益占有率的大部分。除了乳癌之外，卵巢癌、多发性骨髓瘤、肝癌在2015年也占了很大的份额。阿霉素在肝癌治疗中的应用正在迅速扩大，预计在预测期内该应用将以 7.8% 的最快复合年增长率增长。

脂质体阿霉素市场报告亮点

  • 增加技术先进的阿霉素製剂临床试验的併购和合作伙伴关係将支持市场成长。
  • 亚太地区增加研发投资、改善医疗基础设施以及提高患者对标靶癌症治疗和化疗的认识将推动该地区的市场成长。
  • 预计到 2023 年，Lipodox 製剂将占据 40.0% 的份额，2024 年至 2030 年复合年增长率为 7.3%。

目录

第一章调查方法和范围

第 2 章执行摘要

第三章脂质体阿霉素市场变数、趋势和范围

  • 市场介绍/系统展望
  • 市场规模及成长前景
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 脂质体阿霉素市场分析工具
    • 波特的分析
    • PESTEL分析

第四章脂质体阿霉素市场：依产品估计和趋势分析

  • 细分仪表板
  • 脂质体阿霉素市场：2023 年和 2030 年产品变化分析
  • Doxil/caerix
  • 脂质体
  • 米奥塞特
  • 其他的

第五章脂质体阿霉素市场：应用、估计和趋势分析

  • 细分仪表板
  • 脂质体阿霉素市场：2023 年和 2030 年应用变化分析
  • 乳癌
  • 卵巢癌
  • 爱滋病相关的卡波西氏肉瘤
  • 多发性骨髓瘤
  • 其他的

第六章脂质体阿霉素市场：按分销管道估算和趋势分析

  • 细分仪表板
  • 脂质体阿霉素市场：2023 年和 2030 年分销管道变化分析
  • 医院药房
  • 零售药房
  • 网路药房

第七章脂质体阿霉素市场：区域、估计和趋势分析

  • 2023年及2030年脂质体阿霉素市场占有率（按地区），百万美元
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 丹麦
    • 瑞典
    • 挪威
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特
  • 主要市场参与企业的最新趋势和影响分析
  • 公司分类
  • 企业热力图分析
  • 公司简介
    • Sun Pharmaceutical Industries Ltd.
    • Johnson & Johnson Services, Inc.
    • Merck & Co., Inc.
    • Cipla
    • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
    • Lupin
    • Cadila Pharmaceuticals
    • SRS Life Sciences
    • GSK plc.
    • Pfizer Inc.
    • Sanofi
    • Sigma-Aldrich Co.
简介目录
Product Code: GVR-1-68038-743-8

Liposomal Doxorubicin Market Growth & Trends:

The global liposomal doxorubicin market size is expected to reach USD 1.89 billion by 2030, registering a CAGR of 6.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. The presence of various pipeline products awaiting approval by the U.S. FDA and European Medicines Agency is one of the key attributes of this market. The first liposomal doxorubicin formulation was launched in 1995, namely Doxil/Caelyx by Janssen Products and LP & Myocet by Teva Pharmaceutical Laboratories. Doxil, the brand name of liposomal doxorubicin, is under development, and post its commercialization, the product is expected to create significant value over the next 3 to 4 years.

The increasing U.S. FDA approval for drug production is also anticipated to boost the market. The increasing indication of these drugs for various conditions such as AIDS-related Kaposi sarcoma, multiple myeloma, neuroblastoma, osteosarcoma, and ovarian cancer signifies the growth in demand. The technological advancements in the drugs formulations to overcome the adverse effects on health and also introduction of various types of medication delivery systems, such as coated nanoparticles, are some of the pivotal factors impelling the demand for the drug.

Liposomal doxorubicin is primarily approved for the treatment of myeloma, Kaposi sarcoma, and ovarian cancer. However, due to its wide usage in other conditions as well, in 2015, breast cancer accounted for the maximum revenue of 21.2%. The increasing prevalence of breast cancer is leading to growing demand for chemotherapy treatment, which accounts for the majority of revenue share. Besides breast carcinoma, ovarian cancer, multiple myeloma, and liver cancer also held a significant share in 2015. The use of doxorubicin for liver carcinoma treatment is rapidly growing, and this application is expected to grow with the fastest CAGR of 7.8% over the forecast period.

Liposomal Doxorubicin Market Report Highlights:

  • The increasing number of mergers & acquisitions and partnerships for clinical trials on technologically advanced doxorubicin formulations will boost market growth
  • Increasing investment in Asia Pacific pertaining to the R&D, improving healthcare infrastructure, and heightened patient cognizance regarding targeted cancer therapies and chemotherapy will drive regional market growth
  • The lipodox segment dominated the market with 40.0% share in 2023 and is expected to grow at a CAGR of 7.3% from 2024 to 2030.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Liposomal Doxorubicin Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Liposomal Doxorubicin Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Liposomal Doxorubicin Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Liposomal Doxorubicin Market: Product Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Doxil/Caelyx
    • 4.3.1. Doxil/Caelyx Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Lipodox
    • 4.4.1. Lipodox Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Myocet
    • 4.5.1. Myocet Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Liposomal Doxorubicin Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Liposomal Doxorubicin Market: Application Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Breast Cancer
    • 5.3.1. Breast Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Ovarian Cancer
    • 5.4.1. Ovarian Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.5. AIDS-Related Kaposi's Sarcoma
    • 5.5.1. AIDS-Related Kaposi's Sarcoma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.6. Multiple Myeloma
    • 5.6.1. Multiple Myeloma Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.7. Other Solid Tumors
    • 5.7.1. Other Solid Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Liposomal Doxorubicin Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Liposomal Doxorubicin Market: Distribution Channel Movement Analysis, 2023 & 2030 (USD Million)
  • 6.3. Hospital Pharmacies
    • 6.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Online Pharmacies
    • 6.5.1. Online Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Liposomal Doxorubicin Market: Regional Estimates & Trend Analysis

  • 7.1. Liposomal Doxorubicin Market Share, By Region, 2023 & 2030, USD Million
  • 7.2. North America
    • 7.2.1. North America Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.2. U.S.
      • 7.2.2.1. U.S. Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.3. Canada
      • 7.2.3.1. Canada Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.2.4. Mexico
      • 7.2.4.1. Mexico Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.3. Europe
    • 7.3.1. Europe Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.2. UK
      • 7.3.2.1. UK Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.3. Germany
      • 7.3.3.1. Germany Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.4. France
      • 7.3.4.1. France Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.5. Italy
      • 7.3.5.1. Italy Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.6. Spain
      • 7.3.6.1. Spain Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.7. Denmark
      • 7.3.7.1. Denmark Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.8. Sweden
      • 7.3.8.1. Sweden Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.3.9. Norway
      • 7.3.9.1. Norway Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.4. Asia Pacific
    • 7.4.1. Asia Pacific Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. Japan
      • 7.4.2.1. Japan Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. China
      • 7.4.3.1. China Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. India
      • 7.4.4.1. India Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.5. Australia
      • 7.4.5.1. Australia Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.6. South Korea
      • 7.4.6.1. South Korea Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.7. Thailand
      • 7.4.7.1. Thailand Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Latin America
    • 7.5.1. Latin America Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. Brazil
      • 7.5.2.1. Brazil Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Argentina
      • 7.5.3.1. Argentina Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Middle East and Africa
    • 7.6.1. Middle East and Africa Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. South Africa
      • 7.6.2.1. South Africa Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. Saudi Arabia
      • 7.6.3.1. Saudi Arabia Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. UAE
      • 7.6.4.1. UAE Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. Kuwait
      • 7.6.5.1. Kuwait Liposomal Doxorubicin Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Recent Developments & Impact Analysis by Key Market Participants
  • 7.8. Company Categorization
  • 7.9. Company Heat Map Analysis
  • 7.10. Company Profiles
    • 7.10.1. Sun Pharmaceutical Industries Ltd.
      • 7.10.1.1. Participant's Overview
      • 7.10.1.2. Financial Performance
      • 7.10.1.3. Product Benchmarking
      • 7.10.1.4. Recent Developments/ Strategic Initiatives
    • 7.10.2. Johnson & Johnson Services, Inc.
      • 7.10.2.1. Participant's Overview
      • 7.10.2.2. Financial Performance
      • 7.10.2.3. Product Benchmarking
      • 7.10.2.4. Recent Developments/ Strategic Initiatives
    • 7.10.3. Merck & Co., Inc.
      • 7.10.3.1. Participant's Overview
      • 7.10.3.2. Financial Performance
      • 7.10.3.3. Product Benchmarking
      • 7.10.3.4. Recent Developments/ Strategic Initiatives
    • 7.10.4. Cipla
      • 7.10.4.1. Participant's Overview
      • 7.10.4.2. Financial Performance
      • 7.10.4.3. Product Benchmarking
      • 7.10.4.4. Recent Developments/ Strategic Initiatives
    • 7.10.5. Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.
      • 7.10.5.1. Participant's Overview
      • 7.10.5.2. Financial Performance
      • 7.10.5.3. Product Benchmarking
      • 7.10.5.4. Recent Developments/ Strategic Initiatives
    • 7.10.6. Lupin
      • 7.10.6.1. Participant's Overview
      • 7.10.6.2. Financial Performance
      • 7.10.6.3. Product Benchmarking
      • 7.10.6.4. Recent Developments/ Strategic Initiatives
    • 7.10.7. Cadila Pharmaceuticals
      • 7.10.7.1. Participant's Overview
      • 7.10.7.2. Financial Performance
      • 7.10.7.3. Product Benchmarking
      • 7.10.7.4. Recent Developments/ Strategic Initiatives
    • 7.10.8. SRS Life Sciences
      • 7.10.8.1. Participant's Overview
      • 7.10.8.2. Financial Performance
      • 7.10.8.3. Product Benchmarking
      • 7.10.8.4. Recent Developments/ Strategic Initiatives
    • 7.10.9. GSK plc.
      • 7.10.9.1. Participant's Overview
      • 7.10.9.2. Financial Performance
      • 7.10.9.3. Product Benchmarking
      • 7.10.9.4. Recent Developments/ Strategic Initiatives
    • 7.10.10. Pfizer Inc.
      • 7.10.10.1. Participant's Overview
      • 7.10.10.2. Financial Performance
      • 7.10.10.3. Product Benchmarking
      • 7.10.10.4. Recent Developments/ Strategic Initiatives
    • 7.10.11. Sanofi
      • 7.10.11.1. Participant's Overview
      • 7.10.11.2. Financial Performance
      • 7.10.11.3. Product Benchmarking
      • 7.10.11.4. Recent Developments/ Strategic Initiatives
    • 7.10.12. Sigma-Aldrich Co.
      • 7.10.12.1. Participant's Overview
      • 7.10.12.2. Financial Performance
      • 7.10.12.3. Product Benchmarking
      • 7.10.12.4. Recent Developments/ Strategic Initiatives